Professor Claude Wischik, Chairman of TauRx, to Present Data Demonstrating the Demographic and Societal Impact of Alzheimer's Disease in Asia

AsiaNet 52774

TAIPEI, Taiwan, Apr. 19/PRN=KYODO JBN / --

        The presentation will be given at the 2013 Alzheimer's Disease

             International [ADI] Conference in Taipei, Taiwan

    Professor Claude Wischik, Chairman of TauRx Therapeutics Ltd and pioneering

researcher in tau pathology and Alzheimer's Disease, will be speaking at the

28th Conference of Alzheimer's Disease International. The global 3-day

conference brings together more than 1,000 medical professionals, dementia

experts, family carers, people living with dementia and national Alzheimer

associations from more than 60 countries. This year's conference theme is aptly

called 'Dementia: Action for Global Change.'

    (Logo: http://photos.prnewswire.com/prnh/20130418/610664 )

    As a Silver Sponsor at this year's ADI conference, TauRx is affirming its

corporate support and commitment to the Alzheimer's Disease International's

call to action for global change in dementia - a commitment of significant

importance in the wake of several failed clinical trials involving beta amyloid

agents and a recent statement by yet another major pharmaceutical company

halting its research in Alzheimer's.

    Today at 14:45 pm, Professor Wischik will present details about the

rationale for conducting tau-based therapeutic clinical research in China for

Alzheimer's, and the economic and societal consequences of failing to do so.

    Using demographic data from the World Health Organization, together with a

proven cognitive staging system used to assess the severity of Alzheimer's

based on the presence of tau tangles [tau pathology] in the brain, Professor

Wischik will demonstrate why up to 155 million people in Asia will advance to

moderate to severe Alzheimer's by 2050. Of major concern is the possibility

that as many as one billion people will be at risk for earlier stages of

Alzheimer's Disease.

    TauRx Therapeutics recently launched Phase 3 clinical trials of its tau

aggregation inhibitor, LMTX(TM), a compound which targets the formation of tau

'tangles' in the brain, and which aims to slow or halt the progression of

Alzheimer's Disease in those with mild to moderate stages of the disease.

Patients and carers can find further information at http://www.alzdirectory.org.

    About TauRx Therapeutics:

    TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of

developing new treatments and diagnostics for a range of neurodegenerative

diseases. The company's tau aggregation inhibitor, LMTX(TM), is currently in

global Phase 3 clinical trials for Alzheimer's and Frontotemporal Dementia

(FTD). LMTX(TM) targets aggregates of abnormal fibres of tau protein that form

inside nerve cells in the brain, giving rise to tangles. TauRx's primary

research facilities are in Aberdeen, Scotland.

    For press enquiries please contact:

    Email: press@taurx.com

    Website: http://www.taurx.com

    SOURCE: TauRx Therapeutics Ltd